Navigation Links
NLP Logix Announces Joint Product Development Agreement with Mayo Clinic using Deep Learning and Deployment onto Microsoft Azure
Date:7/26/2017

NLP Logix today announced a collaboration to develop deep learning algorithms targeted towards leveraging the years of diagnostic excellence by Mayo Clinic and the experience in developing and deploying artificial intelligence solutions by NLP Logix. The first product suite will be distributed through the Microsoft Azure platform and will focus on assisting physicians to more accurately and efficiently diagnose strokes in patients, one of the leading causes of death and debilitation in the world.

Artificial intelligence has most recently been associated with self-driving cars, facial recognition on FaceBook and Google, and Amazon’s home device offerings. This collaboration with Mayo Clinic is intended to bring this breakthrough technology to healthcare.

“This collaboration is bringing together the clinical expertise of Mayo Clinic, the extensive deep learning infrastructure and experience we have gained over the past six years here at NLP Logix, and the ability to quickly distribute these models via Azure,” said Matt Berseth, Lead Scientist, NLP Logix. “Artificial intelligence takes massive amounts of data to achieve results that are on par with humans and accurate data is essential to success. We're excited to collaborate with the world-renowned Mayo Clinic to develop products for the healthcare industry and we know we are working with the best to be able to deliver significant clinical value.”

“We are excited to be on the forefront of delivering the promise of artificial intelligence to improve patient care,” said W. David Freeman, M.D., neurologist at the Mayo Clinic campus in Florida. “To begin, we are focusing on developing a suite of stroke detection algorithms, which will be trained using the vast amount of de-identified clinical data Mayo Clinic has collected over the years.

The growing number of data science competitions sponsored by industry leading technology companies in collaboration with clinical research organizations across the world, highlight the significance of research in the area of deep learning in healthcare. This collaboration between NLP Logix, Mayo Clinic and Microsoft, will accelerate bringing deep learning theory from the lab to deliver real world value to the patient.

“Deep learning has shown early promise to be able to make significant contributions to the science of medicine and improve patient care,” said Charles Bruce, M.D., cardiologist at the Mayo Clinic campus in Florida. “We are excited to accelerate the potentials of artificial intelligence into true clinical value to our patients across the world.”

Mayo Clinic, Dr. W. David Freeman and Dr. Charles Bruce have a financial interest in the technology referenced in this news release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.

About NLP Logix
NLP Logix is an advanced analytics and machine learning data product and services company, which has grown from a vision in 2011 to one of the fastest growing teams of deep learning practitioners. NLP Logix delivers its solutions through LogixStudio, the company’s proprietary platform that gives a customer the ability to quickly leverage the growing library of algorithms and deploy them into their workflow. NLP Logix is delivering predictive modeling and machine learning solutions to customers across a wide swath of industries, including financial services, energy, healthcare, government, human resources and others. NLP Logix was recently recognized as one of the top 50 Fastest Growing Companies in Northeast Florida by the Jacksonville Business Journal for the second year in a row. For more information, please visit http://www.nlplogix.com.

Read the full story at http://www.prweb.com/releases/2017/07/prweb14542277.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Resverlogix desincorpora RVX Therapeutics Inc. para sus accionistas
2. Resverlogix Announces Annual General Meeting Voting Results
3. Resverlogix Names Michael Sweeney, M.D., as Senior Vice President of Clinical Development
4. Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program
5. Resverlogix Presents at the Prestigious American College of Cardiology 64th Annual Scientific Session & Expo (ACC.15)
6. Resverlogix Receives Two Patents for RVX-208 in China
7. Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA)
8. Resverlogix Reports on the Beneficial Effects of RVX-208 on Glucose Metabolism in Prediabetes Mellitus at the American Diabetes Associations (ADA) Scientific Sessions in Boston, MA
9. Resverlogix to Present at the 2015 Bio International Convention
10. Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority
11. Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for ... June 2018 in San Francisco, CA. The Summit brings together current and former FDA ... board directors and government officials from around the world to address key issues in ...
(Date:10/11/2017)... INDIANAPOLIS , Oct. 11, 2017  VMS BioMarketing, a ... of a nationwide oncology Clinical Nurse Educator (CNE) network, which ... growing need for communication among health care professionals to enhance ... physicians, nurses, office staff, and other health care professionals to ... for breast cancer. ...
(Date:10/11/2017)... ... , ... Disappearing forests and increased emissions are the main causes of the ... Especially those living in larger cities are affected by air pollution related diseases. , ... pollution-affected countries globally - decided to take action. , “I knew I had to ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology ... drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription ... is able to cross the cell membrane and bind intracellular STAT3 and inhibit ...
Breaking Biology Technology:
(Date:4/19/2017)... 19, 2017 The global military ... is marked by the presence of several large global ... by five major players - 3M Cogent, NEC Corporation, ... for nearly 61% of the global military biometric market ... the global military biometrics market boast global presence, which ...
(Date:4/13/2017)... Calif. , April 13, 2017 UBM,s ... York will feature emerging and evolving technology ... Both Innovation Summits will run alongside the expo portion ... speaker sessions, panels and demonstrations focused on trending topics ... largest advanced design and manufacturing event will take place ...
(Date:4/11/2017)... Apr. 11, 2017 Research and Markets has ... report to their offering. ... The global eye tracking market to grow at a CAGR of ... Eye Tracking Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
Breaking Biology News(10 mins):